25 drugs are cutting prices in many places. Experts: opportunities for pharmaceutical companies are still there

[industry trends of pharmaceutical network] the pilot of centralized purchase and use of drugs organized by the state was originally carried out in 4 municipalities directly under the central government and 7 large cities, and then expanded to the whole country, forming a national major Alliance for centralized purchase On September 25 this year, the results of the pilot expansion were officially announced There are 25 kinds of related drugs, mainly including cardiovascular diseases, epilepsy, hepatitis and anti-tumor drugs, with an average decrease of 59% I have learned that recently, there have been many news of drug price reduction Medicine (picture source: pharmaceutical network) For example, on December 18, the centralized purchase and use of drugs organized by the state was fully implemented in Liaoning Province, and the prices of common drugs purchased in centralized volume in 25 national organization alliance regions will be reduced in an all-round way All public medical and health institutions in Liaoning Province and military medical institutions in Liaoning medical insurance fixed point uniformly implement the centralized purchase results of drugs in the alliance region (Liaoning Province) The prices of 25 drugs selected are the same as those in 2018 Compared with the low purchase price, the average decrease was 59% On December 16, the website of Hainan Public Resources Trading Service Center released the notice on publicizing the price reduction of the non selected varieties in the expansion of centralized drug procurement After the end of the publicity period, the price of the non objectionable varieties will be reduced, and the non price reduced varieties will be removed from the network After sorting out, there are 149 product regulations in Hainan that choose to reduce the price It is understood that up to now, many places have issued "4 + 7" rules on price adjustment for drugs that are not selected in centralized purchase In addition to Liaoning and Hainan, several cities, such as Shanghai, Sichuan, Xi'an, Chongqing, Shenzhen, Guangzhou, Tianjin, Shanxi and Shaanxi, have already issued documents requiring "4 + 7" drugs of the same variety that are not selected for gradient price reduction Through purchasing with quantity and exchanging price with quantity, we can reduce the burden of patients, save the expenditure of medical insurance fund, improve the efficiency of medical insurance fund, and improve the level of medical insurance for the common people Some experts said, "there are 25 selected drugs this time, including classic chemotherapy drugs for lung cancer and a kind of original research drug in the field of combined treatment Each treatment cycle (21 days) has dropped from more than 20000 yuan just entering China to 5201 yuan today At the same time, the drug has entered the medical insurance catalog, and a single course of treatment only needs 1000 yuan at one's own expense." Calculated in one year, the accumulated drug cost is from more than 400000 yuan to about 17000 yuan The economic burden of patients has been significantly reduced, and more patients can afford to eat and use it " However, some people also ask: the state organizes the centralized procurement of drugs with a large volume, and the prices of generic drugs and original research drugs are greatly reduced, and the national medical insurance drug negotiations, many new drugs are offered at a global low price Then, will the decrease in the revenue of pharmaceutical enterprises affect the research and development of innovative drugs and generic drugs? In this regard, some experts said that innovative drugs are the trend of future development Both capital market and policy conditions are good for innovative drugs And a new global drug, it is facing the global market, even if there is a certain price pressure in China, but the patient population in China is too large, even some rare diseases may not be so rare in China For a truly innovative drug, the huge market in China and the opportunities in the global market, it is possible for pharmaceutical companies to obtain innovation returns   In view of the impact and challenges that generic pharmaceutical enterprises have been facing in recent years, the above experts said that they believe that the traditional domestic generic pharmaceutical enterprises have accumulated a lot of resources in the steady development process, whether it is the industrial foundation, financial support or sales channels, which are their advantages, recognize the advantages and do a good job of coordination, select varieties and make characteristics, starting with micro innovation, It's all their chance